Emerald Advisers LLC Buys 4,059 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Emerald Advisers LLC boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 94.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,338 shares of the biotechnology company's stock after purchasing an additional 4,059 shares during the period. Emerald Advisers LLC's holdings in Sarepta Therapeutics were worth $1,041,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SRPT. Nordea Investment Management AB boosted its holdings in Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company's stock worth $8,004,000 after purchasing an additional 33,711 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $607,000. Teachers Retirement System of The State of Kentucky bought a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at approximately $4,771,000. Securian Asset Management Inc. acquired a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $1,187,000. Finally, Natixis Advisors LLC bought a new stake in Sarepta Therapeutics during the second quarter worth approximately $1,918,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Price Performance

NASDAQ SRPT traded down $0.22 during trading hours on Monday, reaching $123.07. 973,203 shares of the company's stock were exchanged, compared to its average volume of 1,228,809. The firm has a fifty day moving average of $127.42 and a 200-day moving average of $132.77. Sarepta Therapeutics, Inc. has a one year low of $75.85 and a one year high of $173.25. The stock has a market cap of $11.74 billion, a PE ratio of 274.78 and a beta of 0.81. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.06. The business had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm's quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.27) EPS. On average, equities research analysts predict that Sarepta Therapeutics, Inc. will post 1.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SRPT has been the subject of a number of analyst reports. Cantor Fitzgerald restated a "neutral" rating and issued a $152.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Raymond James reaffirmed an "outperform" rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Evercore ISI upgraded Sarepta Therapeutics from an "in-line" rating to an "outperform" rating and decreased their target price for the company from $185.00 to $179.00 in a research note on Thursday, August 8th. Piper Sandler cut their price target on Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating for the company in a report on Thursday, August 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 14th. Two investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $182.95.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.